Pyridopyrimidinones

US7547695B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Guenter Hoelzemann · Seeheim-Jugenheim, DE
• Helene Crassier · Darmstadt, DE
• Karl-August Ackermann · Ober-Ramstadt, DE
• Wolfgang Staehle · Ingelheim am Rhein, DE
• Alfred Jonczyk · Darmstadt, DE
• Wilfried Rautenberg · Reinheim, DE
• Francesc Mitjans · Igualada, ES
• Elisabet Rosell-Vives · Barcelona, ES
• Jaume Adan · Mataró, ES
• Marta Soler Riera · Barcelona, ES

Key dates

• Filing date: Oct 14, 2004
• Grant date: Jun 16, 2009
• Expiry date: Oct 14, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X′ have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumors.